Primary endpoints for future prophylactic human papillomavirus vaccine trials: Towards infection and immunobridging

The Lancet Oncology

Volumn 16, Issue 5, 2015, Pages e226-e233

  Lowy, Douglas R ^a   Herrero, Rolando ^b   Hildesheim, Allan ^a   Cuzick, Jack ^c   de Sanjose Llongueras, Silvia ^d   Dillner, Joakim ^e   Franceschi, Silvia ^b   Eduardo L Franco, ^f   Garland, Suzanne ^g   Gillison, Maura ^h   Giuliano, Anna R ⁱ   Lehtinen, Matti ^j   Paavonen, Jorma ^k   Palefsky, Joel ^l   Schiffman, Mark ^a   Schiller, John T ^a   Stanley, Margaret ^m   Wheeler, Cosette M ⁿ  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MCGILL UNIVERSITY   (Canada)

^g ROYAL WOMEN'S HOSPITAL   (Australia)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^k UNIVERSITY OF HELSINKI   (Finland)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY TITER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION PREVENTION; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; IMMUNOLOGY; PATHOGENICITY; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84933533810     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70075-6     Document Type: Review

References (44)

1. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
2. Online analysis prediction WHO, (accessed Dec 1, 2014). http://globocan.iarc.fr/old/burden.asp?selection_pop=900&Text-p=World&selection_cancer=4162&Text-c=Cervix+uteri&pYear=13&type=0&window=1&submit=%C2%A0Execute%C2%A0.
3. Howley PM, Schiller JT, Lowy DR Papillomaviruses. Fields Virology 2013, 1662-1703. Wolters Kluwer/Lippincott Williams & Willkins, Philadelphia. 6th edn. D.M. Knipe, P.M. Howley (Eds.).
4. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
5. Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012, 61:258-261. Centers for Disease Control and Prevention (CDC).
6. Herrero R, González P, Markowitz LE Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015, 16:e206-e216.
7. Schiller JT, Müller M Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 2015, 16:e217-e225.
8. Primary end-points for prophylactic HPV vaccine trials: IARC 2014 WHO International Agency for Research on Cancer, (accessed Dec 1, 2014). http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk7/Prophylactic_HPV_VaccineTrials.pdf.
9. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics 2002, 17-23. Council for International Organizations of Medical Sciences.
10. Idänpään-Heikkilä JE, Fluss S The CIOMS view on the use of placebo in clinical trials. Sci Eng Ethics 2004, 10:23-28.
11. Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372:711-723.
12. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
13. Kjær SK, Frederiksen K, Munk C, Iftner T Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
14. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
15. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012, 30(suppl 5):F24-F33.
16. Gardasil™ HPV quadrivalent vaccine VRBPAC Background Document, (accessed July 20, 2014). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf.
17. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013, 121:829-846. the 2012 ASCCP Consensus Guidelines Conference.
18. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
19. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006, 108:264-272. the ASCUS LSIL Triage Study (ALTS) Group.
20. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007, 26:441-446.
21. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. the HPV PATRICIA Study Group.
22. Schiffman M, Wentzensen N Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:553-560.
23. Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014, 32:5087-5097. the CVT Group.
24. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
25. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
26. Herrero R, Wacholder S, Rodríguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011, 1:408-419. the Costa Rica Vaccine Trial Group.
27. Kemp TJ, García-Piñeres A, Falk RT, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26:3608-3616. the Costa Rica Vaccine Trial (CVT) Group.
28. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99. the HPV PATRICIA Study Group.
29. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
30. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
31. Stanley MA, Sudenga SL, Giuliano AR Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014, 13:1027-1038.
32. Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL Antibody avidity measurements in recipients of cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014, 32:3232-3236.
33. Lyseng-Williamson KA Human papillomavirus-16/18 AS04-adjuvanted vaccine (cervarix®): a guide to its two-dose schedule in girls aged 9-14 years in the EU. Paediatr Drugs 2014, 16:247-253.
34. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010, 8:260-270.
35. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6:1242-1250. the CVT Group.
36. Safaeian M, Kemp TJ, Pan DY, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013, 9:1399-1406.
37. Tran NP, Hung CF, Roden R, Wu TC Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res 2014, 193:149-171.
38. Castellsagué X1, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37.
39. Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014, 384:2213-2227.
40. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102:315-324.
41. Gillison ML, Chaturvedi AK, Lowy DR HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113(suppl):3036-3046.
42. Palefsky JM, Rubin M The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am 2009, 36:187-200.
43. Cornall AM, Roberts JM, Garland SM, Hillman RJ, Grulich AE, Tabrizi SN Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer 2013, 133:2253-2258.
44. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012, 30(suppl 5):F34-F54.